期刊
CELL METABOLISM
卷 14, 期 6, 页码 811-818出版社
CELL PRESS
DOI: 10.1016/j.cmet.2011.11.005
关键词
-
资金
- European Union [FP6-2005-LIFESCIHEALTH-6, 037631]
- Fondation Leducq Transatlantic Networks of Excellence
- NWO [40-00506-98-9001]
- National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health
- Netherlands Organisation for Scientific Research [021.001.035]
- Netherlands Heart Foundation [2010T082]
Genome-wide association studies have identified GALNT2 as a candidate gene in lipid metabolism, but it is not known how the encoded enzyme ppGal-NAc-T2, which contributes to the initiation of mucin-type O-linked glycosylation, mediates this effect. In two probands with elevated plasma high-density lipoprotein cholesterol and reduced triglycerides, we identified a mutation in GALNT2. It is shown that carriers have improved postprandial triglyceride clearance, which is likely attributable to attenuated glycosylation of apolipoprotein (apo) C-III, as observed in their plasma. This protein inhibits lipoprotein lipase (LPL), which hydrolyses plasma triglycerides. We show that an apoC-III-based peptide is a substrate for ppGaINAc-T2 while its glycosylation by the mutant enzyme is impaired. In addition, neuraminidase treatment of apoC-III which removes the sialic acids from its glycan chain decreases its potential to inhibit LPL. Combined, these data suggest that ppGaINAc-T2 can affect lipid metabolism through apoC-III glyco-sylation, thereby establishing GALNT2 as a lipid-modifying gene.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据